脾长度进展速率是原发性硬化性胆管炎患者结局的标志物
该研究评估原发性硬化性胆管炎(PSC)患者脾长度随时间的变化(Δ脾长度)作为新型替代标志物的作用,以反映PSC进展的动态性。作者指出单点脾长度测量具有与瞬时弹性成像所测肝硬度相似的预后性能,但绝对值受身高和性别影响且无法评估治疗干预效果,故转而评估个体内脾长度进展速率。
要点
- 单点脾长度测量在PSC中的预后性能与瞬时弹性成像所测肝硬度相似。
- 脾长度测量快速、简便且广泛可用,但绝对值受身高和性别影响。
- 作者评估个体内脾长度变化(Δ脾长度=SL2-SL1)作为新型替代标志物。
核心结论
- 作者评估个体内脾长度随时间的变化(Δ脾长度)作为反映PSC进展动态性的新型替代标志物。
主要发现
- PSC患者常在肝硬化发生前即出现脾脏增大。
- 作者近期证明单点脾长度测量具有与瞬时弹性成像所测肝硬度相似的预后性能。
局限性
- 瞬时弹性成像并非普遍可及,仅测量右肝小部分区域,在肥胖患者中易出错。
- 肝硬度与餐后状态、肝脏炎症和胆道梗阻相关。
- 绝对脾大小取决于身高和性别,单点脾长度测量无法评估治疗干预效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with primary sclerosing cholangitis (PSC) tend to develop progressive liver fibrosis and end-stage liver disease within 10-20 years.1 The International PSC Study Group declared research on surrogate endpoints a high-priority task not least for ongoing clinical trials on novel treatment options.2 The spleen in patients with PSC often enlarges even before cirrhosis develops. Transient elastography (TE) has been investigated as a dynamic and prognostic marker in PSC.3,4 However, TE is not generally accessible, measures only a small part of the right liver, and is prone to errors in obese patients, and liver stiffness is related to postprandial status, liver inflammation, and biliary obstruction.5 We have recently demonstrated that single-point spleen length (SL) measurement has a prognostic performance similar to liver stiffness measured by TE.3,4,6 SL measurement is a fast, simple, and ubiquitously available method. However, absolute spleen size depends on body height and sex,7 and single-point measurement of SL cannot be used to assess the effects of therapeutic interventions. To overcome these issues, we assessed the intra-individual development of spleen size over time (delta spleen length: dSL = SL2 - SL1) to evaluate its role as a novel surrogate marker, which accounts for the dynamic nature of PSC progression.
引用
- Jung F, Cazzagon N, Vettorazzi E, et al. Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2019. PMID: 30616025. doi:10.1016/j.cgh.2018.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。